VYNE Therapeutics GAAP EPS of -$0.43 misses by $0.11
Topics: earnings report financial results GAAP EPS
Read the full article at Seeking Alpha
Part of the story Altimmune Reports Q3 GAAP EPS of -$0.15, Missing Estimates by $0.02 (3 articles)
More World news
- Parsons Reports Strong Third Quarter Results Driven by High-Margin Product Shift
- C.H. Robinson Reports Q3 2026 Earnings Driven by AI Efficiency and Margin Expansion
- Baker Hughes Raises Guidance Amid Surging Data Center Power Demand
- California Supreme Court to Rule on Insurance Overcharge Liability Under Proposition 103
- Federal Court Orders Veterans Guardian to Pay Treble Damages to Disabled Veteran Class
- AIRO Group Holdings Reaffirms 2026 Revenue Growth Guidance Amid $200 Million Drone Backlog
- Nvidia CEO Jensen Huang Resigns Amid Personal Scandal, Raising Uncertainty for Open Source AI Strategy
- Vor Bio and RemeGen Expand Collaboration for Autoimmune Disease Therapy
- EnterpriseDB Hires CMRD Engineering Team to Strengthen Sovereign AI Governance
- Alliant Credit Union Executive Meredith Ritchie Named 2027 Chicago Titan 100 Honoree